The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2019 | Multiple-line TKIs to prolong chemo-free period in EGFRm+ NSCLC
Nicolas Girard, MD, PhD, from Claude Bernard University, Lyon, France discusses the management strategies in EGFRm+ non-small cell lung cancer (NSCLC) patients after completing chemotherapy. Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Prof. Girard explains how multiple lines of EGFR TKIs can be used to target the evolving molecular profile of NSCLC at different stages, focusing on the use osimertinib to treat resistance mutations as the tumor progresses.
